Skip to main content
PMC home page
Springer logoLink to Springer
. 2022 Sep 23;74(6):1326–1327. doi: 10.1007/s43440-022-00410-y

Correction: Oral antiviral treatments for COVID-19: opportunities and challenges

Laila Rahmah 1,2, Sunny O Abarikwu 3,4, Amanuel Godana Arero 5,6, Mickael Essouma 25,26, Aliyu Tijani Jibril 7,8,9, Andrzej Fal 10,11,12, Robert Flisiak 13, Rangarirai Makuku 1,14, Leander Marquez 15,16, Kawthar Mohamed 1,17, Lamin Ndow 18,19, Dorota Zarębska-Michaluk 20, Nima Rezaei 21,22,23, Piotr Rzymski 12,24,✉
PMCID: PMC9510311  PMID: 36149599

Correction: Pharmacological Reports 10.1007/s43440-022-00388-7

The original version of this article unfortunately did not list Mickael Essouma as a co-author who has been involved in the drafting and approving of the manuscript.

A correct list of authors is as follows: Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, Mickael Essouma, Aliyu Tijani Jibril, Andrzej Fal, Robert Flisiak, Rangarirai Makuku, Leander Marquez, Kawthar Mohamed, Lamin Ndow, Dorota Zarębska-Michaluk, Nima Rezaei & Piotr Rzymski.

Along with that “Author contributions” was also updated. The original article has been corrected.

Articles from Pharmacological Reports are provided here courtesy of Springer

RESOURCES